David Perry

David Perry is the Co-Founder & Chairman at Better Therapeutics. David was previously the CEO and Director at Indigo, a company dedicated to harnessing nature to help farmers sustainably feed the planet. Indigo improves grower profitability, environmental sustainability, and consumer health through the use of natural microbiology and digital technologies. During their tenure Indigo raised over $1.2B in funding.

Prior to Indigo, David was the CEO and Co-founder at Anacor Pharmaceuticals. David co-founded Anacor Pharmaceuticals and grew the startup through a 2010 IPO and a multi-billion dollar valuation. The biopharmaceutical company is focused on developing novel small-molecule therapeutics to treat infectious and inflammatory diseases. In May 2016, the company was acquired by Pfizer for $5.2 billion.

David has also founded and been the CEO of Chemdex and the Co-founder and President of Virogen. Prior to their entrepreneurial career, David worked as a refinery supervisor at Exxon.

David Perry received their MBA from Harvard Business School and their BS in Chemical Engineering from The University of Tulsa. David also studied Chemistry at the United States Air Force Academy.